JPH01140064A - Fixing liquid - Google Patents
Fixing liquidInfo
- Publication number
- JPH01140064A JPH01140064A JP62297394A JP29739487A JPH01140064A JP H01140064 A JPH01140064 A JP H01140064A JP 62297394 A JP62297394 A JP 62297394A JP 29739487 A JP29739487 A JP 29739487A JP H01140064 A JPH01140064 A JP H01140064A
- Authority
- JP
- Japan
- Prior art keywords
- formalin
- fixative
- formaldehyde
- methanol
- citric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title abstract description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims abstract description 145
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 57
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 11
- -1 alkali metal salt Chemical class 0.000 claims abstract description 11
- 230000007935 neutral effect Effects 0.000 claims abstract description 10
- 239000001509 sodium citrate Substances 0.000 claims abstract description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910001868 water Inorganic materials 0.000 claims abstract description 9
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000000873 masking effect Effects 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 239000000834 fixative Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 abstract description 7
- 210000000170 cell membrane Anatomy 0.000 abstract description 2
- 230000035515 penetration Effects 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
この発明は生体組織の検査に関し、より詳細には、標本
固定液、標本保存液として利用できる固定液に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to the examination of biological tissue, and more particularly to a fixative that can be used as a specimen fixative or specimen preservation solution.
生体から採取した検体は、固定などの処理を受けて標本
として種々の組織検査に供される。この固定は、組織、
細胞の諸成分、諸形態をできる限り採取前と同じ状態に
保つために、適当な固定液で検体を処理して行われてい
る。A specimen collected from a living body undergoes processing such as fixation and is used as a specimen for various histological examinations. This fixation is performed by tissue,
In order to keep the various components and morphology of the cells as much as possible in the same state as before collection, the specimen is treated with an appropriate fixative.
従来、固定液として、ホルムアルデヒド水溶液である局
方ホルマリン１容量部と水４〜９容量部の組成の１０〜
２０％ホルマリン液、上記ホルマリン液に炭酸カルシウ
ムまたは炭酸、マグネシウムを処理させた中性ホルマリ
ン液、局方ホルマリン１００ＩＩｌｌと水９００１とリ
ン酸１ナトリウムとリン酸２ナトリウムとの組成の１０
％中性緩衝ホルマリン液、エタノールなどがある（「臨
床検査法提要」、第２６版、ＸＸ■−６）。Conventionally, as a fixative, 10 to 10 parts by volume of formalin, which is an aqueous formaldehyde solution, and 4 to 9 parts by volume of water are used.
20% formalin solution, a neutral formalin solution obtained by treating the above formalin solution with calcium carbonate or carbonic acid, magnesium, pharmacopoeia 10% formalin solution, composition of 100IIll of formalin, 9001 of water, monosodium phosphate, and disodium phosphate
% neutral buffered formalin solution, ethanol, etc. (``Clinical Test Methods Compendium'', 26th edition, XX■-6).
しかしながら、従来の固定液のうち、ホルマリンを主成
分とするホルマリン液では、組織の厚さ３〜５龍で１〜
２０の固定完了時間がかかり、固定に時間を要する。ま
た、エタノールなどを主成分とする固定液では、２〜３
時間で固定できるものもあるが、適用範囲が狭く細胞収
縮、赤血球溶解などの固定目的を逸脱する変性を起こす
。However, among conventional fixatives, formalin solution whose main component is formalin,
It takes 20 hours to complete fixing, and it takes time to fix. In addition, with a fixative whose main component is ethanol etc., 2 to 3
Some methods can be fixed over time, but their applicability is limited and they cause degeneration that deviates from the purpose of fixation, such as cell shrinkage and red blood cell lysis.
この発明は上述の背景に基づきなされたものであり、そ
の目的とするところは、迅速に固定することができると
共に、固定効果に優れた固定液を提供することである。This invention was made based on the above-mentioned background, and its purpose is to provide a fixative that can be fixed quickly and has an excellent fixing effect.
本発明者は、上記の課題解決のために種々の研究試験を
行った結果、組織検査処理に際して用いる固定液として
、ホルマリン、メタノールおよびクエン酸またはその塩
を含む液を用いれば、この発明の目的達成に有効である
ことを見出し、この発明を完成するに至った。As a result of conducting various research tests to solve the above-mentioned problems, the present inventor has found that if a solution containing formalin, methanol, and citric acid or a salt thereof is used as a fixative for tissue examination processing, the object of the present invention can be achieved. They have found that this is effective in achieving this goal, and have completed this invention.
すなわち、この発明の固定液は、ホルムアルデヒド、メ
タノール、クエン酸またはそのアルカリ金属塩、および
溶媒としての水を含むことを特徴とするものである。That is, the fixative of the present invention is characterized by containing formaldehyde, methanol, citric acid or an alkali metal salt thereof, and water as a solvent.
この発明による固定液の好ましい態様において、クエン
酸のアルカリ金属塩として、クエン酸ナトリウムを用い
ることができる。In a preferred embodiment of the fixative according to the invention, sodium citrate can be used as the alkali metal salt of citric acid.
この発明による固定液の好ましい一態様において、ホル
ムアルデヒドを、マスク剤を含む脱臭ホルマリンまたは
中性ホルマリンとして混和することができる。In a preferred embodiment of the fixative according to the invention, formaldehyde can be incorporated as deodorized formalin or neutral formalin containing a masking agent.
上述の構成からなるこの発明では、理論的に明らかでは
ないが、ホルマリンに加えられるメタノールの浸透力が
、ホルマリンの浸透力に加算されて全体の固定液の浸透
、および固定の速度を増強し、クエン酸およびそのアル
カリ金属塩が細胞膜の固定効果を良好にならしめる。In this invention having the above configuration, although it is not theoretically clear, the permeation power of methanol added to formalin is added to the permeation power of formalin to enhance the permeation of the entire fixative and the speed of fixation, Citric acid and its alkali metal salts have a good fixing effect on cell membranes.
なお、上述の記載は、この発明のより良い理解のためで
あり、この発明の範囲を限定するものではない。Note that the above description is for a better understanding of the present invention, and does not limit the scope of the present invention.
この発明によって次の効果を得ることができる。 The following effects can be obtained by this invention.
（イ） 迅速に固定することができると共に、固定効果
に優れた固定液を提供することができる。(a) It is possible to provide a fixative solution that can be fixed quickly and has an excellent fixation effect.
（ロ） 安価なホルマリン、メタノールなどを原料とす
るので、製造コストを低減することができる。(b) Since inexpensive formalin, methanol, etc. are used as raw materials, manufacturing costs can be reduced.
（ハ） 迅速に固定することができるので、検体採取後
短時間で標本ができ、病理診断確定までの時間を著しく
短縮することができる。(c) Since the specimen can be fixed quickly, a specimen can be prepared in a short period of time after specimen collection, and the time required to establish a pathological diagnosis can be significantly shortened.
（ニ） 固定効果に優れているので、組織、細胞の諸成
分、諸形態をできる限り採取前と同じ状態に保つことが
できる。(d) Since it has an excellent fixation effect, it is possible to maintain the various components and forms of tissues and cells as much as possible in the same state as before collection.
（ホ） この固定液は、脳組織を含む全ての材料に使用
でき、しかも、生検および９す検両方に適用できる。(e) This fixative can be used for all materials including brain tissue, and can be applied to both biopsies and autopsies.
以下、この発明をより詳細に具体的に説明する。Hereinafter, this invention will be specifically explained in more detail.
この発明の固定液は、ホルムアルデヒド、メタノールお
よび、クエン酸またはそのアルカリ金属塩を含むことを
特徴とするものである。The fixative of the present invention is characterized by containing formaldehyde, methanol, and citric acid or an alkali metal salt thereof.
ホルムアルデヒドは、通常、ホルムアルデヒドの水溶液
であるホルマリンとして用いる。この発明において用い
られるホルマリンは、特に、その濃度に制限はない。通
常用いることができるホルマリンは、３７％以上、例え
ば、３７〜４０％のホルムアルデヒドを含有する局方ホ
ルマリンである。Formaldehyde is usually used as formalin, which is an aqueous solution of formaldehyde. There are no particular limitations on the concentration of formalin used in this invention. Formalin that can usually be used is pharmacopoeial formalin containing 37% or more formaldehyde, for example 37-40%.
この発明で用いることができる好ましいホルマリンは、
ホルマリン原液に炭酸カルシウムまたは炭酸マグネシウ
ムを処理させた中性ホルマリン液、または、マスク剤を
含む脱臭ホルマリンである。Preferred formalin that can be used in this invention is:
Neutral formalin solution obtained by treating formalin stock solution with calcium carbonate or magnesium carbonate, or deodorized formalin containing a masking agent.
ここで用いることができるマスク剤として、サリチル酸
メチル、メントールなどの付番剤がある。Masking agents that can be used here include numbering agents such as methyl salicylate and menthol.
この中性ホルマリンを用いることにより、副生物である
ギ酸を中和・除去して良好な固定を確保し、脱臭ホルマ
リンを使用することにより、ホルムアルデヒドの臭いを
隠蔽することができる。By using this neutral formalin, the by-product formic acid can be neutralized and removed to ensure good fixation, and by using deodorized formalin, the odor of formaldehyde can be hidden.
なお、この発明においては、ホルマリンとして使用する
ことが必須ではなく、最終製品である固定液中にホルム
アルデヒドを所定量含めれば良い。In this invention, it is not essential to use formaldehyde as formalin, but it is sufficient to include a predetermined amount of formaldehyde in the final product, the fixative.
したがって、ホルムアルデヒドと他の成分とを混合した
後、水で希釈しても、またホルムアルデヒドと他の成分
と水とを同時混合しても、さらに、ホルムアルデヒドと
他の成分の水溶液とを混合して、目的の固定液を調製す
ることができる。Therefore, whether formaldehyde and other components are mixed and then diluted with water, formaldehyde, other components, and water are simultaneously mixed, or formaldehyde and an aqueous solution of other components are mixed together. , the desired fixative solution can be prepared.
この発明において用いることができるクエン酸は、ヒド
ロキシトリカルボン酸であり、その塩として、クエン酸
ナトリウム、クエン酸カリウム、クエン酸カルシウム、
クエン酸アンモニウムなどがある。好ましいクエン酸塩
は、ナトリウム塩などのアルカリ金属塩である。Citric acid that can be used in this invention is hydroxytricarboxylic acid, and its salts include sodium citrate, potassium citrate, calcium citrate,
Examples include ammonium citrate. Preferred citrates are alkali metal salts such as sodium salts.
この発明の固定液の組成は、検体の稲類、迅速性の程度
などに応じて適宜選択することができる。The composition of the fixative of the present invention can be appropriately selected depending on the rice species to be tested, the degree of rapidity, etc.
下記にその例を示す。An example is shown below.
なお、この組成例では、ホルムアルデヒドはホルムアル
デヒド３７９６６有するホルマリンとして、また、クエ
ン酸塩は１０％水溶液として用いる。In this composition example, formaldehyde is used as formalin containing 37966 formaldehyde, and citrate is used as a 10% aqueous solution.
この発明の固定液の組成は、例えば、ホルマリン１０〜
８０容量部、メタノール１０〜８０容量部（但し、ホル
マリンの容量と同じまたはそれより少ないことが好まし
い）、クエン酸塩液１〜３０容二部であり、好ましくは
、ホルマリン２５〜７５容量部、メタノール２５〜７５
容量部（但し、ホルマリンの容量と同じまたはそれより
少ないことが好ましい）、クエン酸塩液５〜２０容量部
であり、より好ましくは、ホルマリン３０〜７０容量部
、メタノール２５〜７０容量部（但し、ホルマリンの容
量と同じまたはそれより少ないことが好ましい）、クエ
ン酸塩液８〜１７容量部である。The composition of the fixative of this invention is, for example, formalin 10 to
80 parts by volume, 10 to 80 parts by volume of methanol (preferably the same as or less than the volume of formalin), 1 to 30 parts of citrate solution, preferably 25 to 75 parts by volume of formalin, Methanol 25-75
parts by volume (preferably the same as or less than the volume of formalin), 5 to 20 parts by volume of citrate solution, more preferably 30 to 70 parts by volume of formalin, and 25 to 70 parts by volume of methanol (however, , preferably the same as or less than the volume of formalin), 8 to 17 parts by volume of citrate solution.
上記した成分の他に、目的に応じて種々の添加剤を含め
ることができる。In addition to the above-mentioned components, various additives can be included depending on the purpose.
次いで、この発明の固定液の使い方の一例を説明する。Next, an example of how to use the fixative of the present invention will be explained.
採取した組織片をこの固定液またはこの固定液を水で希
釈した液に入れ、振盪しなが−ら固定する。例えば、厚
さ５ＩＩＩｍの組織片では２〜３時間で固定される。次
いで、固定が完了した組織片は直ちに包埋器に装入して
パラフィンで包埋する。The collected tissue piece is placed in this fixative or a solution diluted with water and fixed while shaking. For example, a tissue piece with a thickness of 5IIIm is fixed in 2 to 3 hours. Next, the fixed tissue piece is immediately placed in an embedding device and embedded in paraffin.
パラフィン包埋が完成して後、直ちに薄切り、染色して
染色標本を作製することができる。After paraffin embedding is completed, a stained specimen can be prepared by immediately slicing and staining.
この発明を、以下の例によって具体的に説明する。 This invention will be specifically explained by the following examples.
製造例 下記組成の固定液１〜５を調製した。Manufacturing example Fixative solutions 1 to 5 having the following compositions were prepared.
第１表 組成
Ｎｏ、１ 固定液１
中性ホルマリン ５０．０容量％メタノー
ル ３７．５容量％１０％クエン酸ナ
トリウム液 １２．５容量％ＮＯ１２固定液２
ホルマリン ４５．０容量％メタノー
ル ４５．０容量％１０％クエン酸ナ
トリウム液 １０，０容量％Ｎｏ、 ３
固定液３
ホルマリン ６５，０容量％メタノー
ル ２５，０容量％１０％クエン酸ナ
トリウム液 １０，０容量％Ｎｏ、４ 固定
液４
脱臭ホルマリン ６５．０容量％メタノー
ル ２５，０容量％ｌＯ％クエン酸ナ
トリウム液 １０．０容量％Ｎｏ、 ５
固定液５
脱臭中性ホルマリン ５５．０容量％メタノー
ル ３５．０容量％１０％クエン酸ナ
トリウム液 ２０．０容量％使用例１
前記製造例で示した固定液を用いて、剖検例の肝を材料
として固定した。その結果、１時間で約１．７５ｍ＋ｓ
、’）時間で約２．７５ｍ＋＊の速さで浸透し固定が完
了した。なお、２４時間後には、約７．５關にも達した
。その結果を第１図に示す。Table 1 Composition No. 1 Fixative solution 1 Neutral formalin 50.0% by volume Methanol 37.5% by volume 10% sodium citrate solution 12.5% by volume NO12 Fixative solution 2 Formalin 45.0% by volume Methanol 45.0 volume %10% Sodium Citrate Solution 10.0 Volume% No. 3
Fixative solution 3 Formalin 65.0% by volume Methanol 25.0% by volume 10% Sodium citrate solution 10.0% by volume No. 4 Fixative solution 4 Deodorized formalin 65.0% by volume Methanol 25.0% by volume 10% Sodium citrate Liquid 10.0% by volume No. 5
Fixative solution 5 Deodorized neutral formalin 55.0% by volume Methanol 35.0% by volume 10% sodium citrate solution 20.0% by volume Usage example 1 Using the fixative shown in the above production example, the liver of an autopsy sample was prepared. It was fixed as As a result, approximately 1.75m+s in 1 hour
It penetrated at a speed of about 2.75 m+* in ,') hours and the fixation was completed. In addition, after 24 hours, it reached about 7.5 degrees. The results are shown in FIG.
比較のために、５０％ホルマリン、２０％ホルマリン、
１０％ホルマリンについて同様に試験した。従来の固定
液に比べると著しく固定速度が改善されているを示して
いる。For comparison, 50% formalin, 20% formalin,
A similar test was conducted for 10% formalin. This shows that the fixation speed is significantly improved compared to conventional fixatives.
使用例２
本発明の固定液を、核や細胞質の固定性について、単純
なホルマリン・メタノール混合液、２０％ホルマリン液
、５０％ホルマリン液の場合と比較した。その結果、ホ
ルマリン・メタノール混合液に比べて極めて優れており
、その他のホルマリン液に勝るとも劣らない固定性を示
した。Use Example 2 The fixative of the present invention was compared with a simple formalin/methanol mixture, a 20% formalin solution, and a 50% formalin solution in terms of fixation of nuclei and cytoplasm. As a result, the fixation properties were extremely superior to that of a formalin/methanol mixture, and were comparable to other formalin solutions.
特に、中性ホルマリンを使用した場合、いわゆるホルマ
リン色素（沈若物）の沈着が殆ど無く、しかも固定液中
に組織片を長時間浸しておいても過固定による染色性の
劣化は最少銀にすることができた。In particular, when using neutral formalin, there is almost no deposition of so-called formalin pigment (sediments), and even if the tissue piece is immersed in the fixative for a long time, there is minimal deterioration of staining properties due to overfixation. We were able to.
第１図は、使用例１の固定結果を示す線図である。 出願人代理人 佐 藤 −雄 第１図 FIG. 1 is a diagram showing the fixation results of usage example 1. Applicant's representative: Mr. Sato Figure 1
Claims (1)
のアルカリ金属塩、および溶媒としての水を含むことを
特徴とする固定液。 ２、クエン酸のアルカリ金属塩が、クエン酸ナトリウム
である特許請求の範囲第１項記載の固定液。 ３、ホルムアルデヒトが中性ホルマリンとして混和され
る特許請求の範囲第１項または第２項記載の固定液。 ４、ホルムアルデヒトが、マスク剤を含む脱臭ホルマリ
ンとして混和される特許請求の範囲第１項乃至第２項の
いずれかに記載の固定液。[Claims] 1. A fixative containing formaldehyde, methanol, citric acid or an alkali metal salt thereof, and water as a solvent. 2. The fixative according to claim 1, wherein the alkali metal salt of citric acid is sodium citrate. 3. The fixative according to claim 1 or 2, in which formaldehyde is mixed as neutral formalin. 4. The fixative according to any one of claims 1 to 2, wherein formaldehyde is mixed as deodorized formalin containing a masking agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62297394A JPH068818B2 (en) | 1987-11-27 | 1987-11-27 | Fixative for biopsy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62297394A JPH068818B2 (en) | 1987-11-27 | 1987-11-27 | Fixative for biopsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01140064A true JPH01140064A (en) | 1989-06-01 |
| JPH068818B2 JPH068818B2 (en) | 1994-02-02 |
Family
ID=17845922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62297394A Expired - Lifetime JPH068818B2 (en) | 1987-11-27 | 1987-11-27 | Fixative for biopsy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH068818B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024041A1 (en) * | 1995-02-03 | 1996-08-08 | Teiji Takezaki | Method of fixedly supporting biopsy specimen, fixedly supporting agent, and embedding cassette |
| US5976829A (en) * | 1994-04-22 | 1999-11-02 | Birnboim; Hyman C. | Dual purpose tissue fixative |
| KR100706549B1 (en) * | 2005-11-30 | 2007-04-13 | 현대자동차주식회사 | Mounting method of key for a damper pulley |
| WO2014069519A1 (en) * | 2012-10-30 | 2014-05-08 | 学校法人金沢医科大学 | Kit for producing transparentized biological specimen, and method for producing transparentized biological specimen |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5049026A (en) * | 1973-06-25 | 1975-05-01 | ||
| JPS5391115A (en) * | 1977-01-20 | 1978-08-10 | Honma Kenkyusho | Production of preserving solution for blood corpuscle |
-
1987
- 1987-11-27 JP JP62297394A patent/JPH068818B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5049026A (en) * | 1973-06-25 | 1975-05-01 | ||
| JPS5391115A (en) * | 1977-01-20 | 1978-08-10 | Honma Kenkyusho | Production of preserving solution for blood corpuscle |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976829A (en) * | 1994-04-22 | 1999-11-02 | Birnboim; Hyman C. | Dual purpose tissue fixative |
| WO1996024041A1 (en) * | 1995-02-03 | 1996-08-08 | Teiji Takezaki | Method of fixedly supporting biopsy specimen, fixedly supporting agent, and embedding cassette |
| US5968436A (en) * | 1995-02-03 | 1999-10-19 | Takezaki; Teiji | Method of fixedly supporting biopsy specimen and embedding cassette |
| KR100706549B1 (en) * | 2005-11-30 | 2007-04-13 | 현대자동차주식회사 | Mounting method of key for a damper pulley |
| WO2014069519A1 (en) * | 2012-10-30 | 2014-05-08 | 学校法人金沢医科大学 | Kit for producing transparentized biological specimen, and method for producing transparentized biological specimen |
| US11035763B2 (en) | 2012-10-30 | 2021-06-15 | Kanazawa Medical University | Kit for producing cleared biological specimens and method for producing cleared biological specimens |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH068818B2 (en) | 1994-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laidlaw et al. | Melanoma studies: II. A simple technique for the dopa reaction | |
| Kalweit et al. | A national validation project of alternative methods to the Draize rabbit eye test | |
| Cain | An examination of Baker’s acid haematein test for phospholipines | |
| Cole | Practical physiological chemistry | |
| Squier et al. | In-vitro permeability of porcine oral mucosa after epithelial separation, stripping and hydration | |
| DE2648458A1 (en) | REAGENT FOR THE DIAGNOSIS OF CANCER, ITS PRODUCTION AND APPLICATION | |
| Mekota et al. | Determination of optimal rehydration, fixation and staining methods for histological and immunohistochemical analysis of mummified soft tissues | |
| JP2008530526A (en) | Reagent for stabilizing cells by permeabilization and method of using the same | |
| Fullmer et al. | A selective stain for elastic tissue (orcinol-new fuchsin) | |
| CA2865584A1 (en) | Formalin-free fixation agent for histological stains of tissue samples | |
| Naftalin et al. | The character of the tectorial membrane | |
| JPH01140064A (en) | Fixing liquid | |
| JP4292296B2 (en) | Electron staining method for samples for transmission electron microscope observation. | |
| Cole | Practical physiological chemistry | |
| CN107621462A (en) | A kind of transparency of organization liquid SUT and its preparation and application | |
| JPH0746100B2 (en) | Cell fixing / preservation solution | |
| DE102013200256B3 (en) | Detecting tumor cells in samples of human or animal tissue, comprises treating sample with complex of fluorophore as guest and macrocyclic material as host, and then irradiating with a light that is suitable for exciting the fluorophore | |
| Connor | Studies on Lipochromes: IV. The Nature of the Pigments in Certain Organs | |
| Flesch et al. | Laboratory methods for studying percutaneous absorption and the chemical effects of topical agents upon human skin | |
| Lewin et al. | Softening techniques for nail biopsies | |
| Lang et al. | Ultrasonic absorption in the human breast cyst liquids | |
| Kang et al. | Histological techniques for decalcified bone and cartilage | |
| Antonini et al. | Enzymatic activities in the perilymph phosphohexoseisomerase and lacticdehydrogenase | |
| Turello et al. | A modification the osmium tetroxide post-fixation technique for the demonstration of extracellular lipid in paraffin-embedded tissue sections | |
| JPH0746101B2 (en) | Cell fixative / preservative solution with mucolytic properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |